JP7049868B2 - Antiperspirant composition - Google Patents

Description

The present invention relates to an antiperspirant composition.

Antiperspirant components such as aluminum salts and bactericidal components are used in roll-on type and lotion type antiperspirants that use water as a solvent. Further, it is known that an emulsifier such as a nonionic surfactant is used when an oily component is added for the purpose of imparting a feel (see, for example, Patent Document 1).
However, after applying such an antiperspirant to the skin, the water of the solvent volatilizes, causing the aluminum salt to whiten on the skin, achieving both an antiperspirant effect and no white residue on the skin. There was the problem that it was difficult to do.

Therefore, there is a strong demand for the development of an antiperspirant composition that can suppress white residue on the skin while maintaining the antiperspirant effect.

Japanese Unexamined Patent Publication No. 2013-75870

An object of the present invention is to solve the above-mentioned problems in the prior art and to achieve the following objects. That is, the present invention has no stickiness, skin tension, or irritation to the skin after application of the antiperspirant composition, is excellent in deodorant effect and stability of the preparation, and maintains the antiperspirant effect. It is an object of the present invention to provide an antiperspirant composition capable of suppressing white residue on the skin.

As a result of diligent studies by the present inventor to solve the above problems, (A) antiperspirant component, (B) bactericidal component, (C) triglyceride (C1), fatty acid isoamyl (C2), and linear chain. At least one selected from the alkyl-modified silicones (C3), polyoxyethylene alkyl ethers having an average added mole number of (D1) ethylene oxide of 2 or more and 8 or less, and (D2) ethylene oxide having an average added molar number of 8 or less. When 10 or more and 30 or less of polyoxyethylene alkyl ether and (E) water were blended, these components acted synergistically to make the skin sticky, taut, and skin after applying the antiperspirant composition. It was found that there is no irritation to the skin, the deodorant effect and the stability of the preparation are excellent, and the white residue of the skin can be suppressed while maintaining the antiperspirant effect.

The present invention is based on the above-mentioned knowledge by the present inventor, and the means for solving the above-mentioned problems are as follows.
<1> (A) An aluminum compound, a zirconium compound, and at least one antiperspirant component selected from these complexes, and
(B) Bactericidal component and
(C) At least one selected from triglyceride (C1), fatty acid isoamyl (C2), and linear alkyl-modified silicone (C3).
(D1) Polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added of 2 or more and 8 or less,
(D2) Polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added of 10 or more and 30 or less,
(E) Contains water and
The antiperspirant composition is characterized in that the content of the component (E) is 65% by mass to 90% by mass.
<2> The component (C1) and the component (C2) are contained.
The antiperspirant composition according to <1>, wherein the mass ratio (C1 / C2) of the content of the component (C1) to the content of the component (C2) is 0.5 to 2. ..
<3> The antiperspirant composition according to any one of <1> to <2>, wherein the component (A) is chlorohydroxyaluminum.
<4> The antiperspirant according to any one of <1> to <3>, wherein the component (B) is at least one selected from cetylpyridinium chloride, benzalkonium chloride, and isopropylmethylphenol. It is a composition.
<5> The component (C1) is at least one selected from tri (caprylic acid / caprylic acid) glyceryl and caprylic acid triglyceride.
The component (C2) is at least one selected from isoamyl laurate, isoamyl caprate, and isoamyl coconut oil fatty acid.
The antiperspirant composition according to any one of <1> to <4>, wherein the component (C3) is at least one selected from cetyldimethicone, stearyldimethicone, and caprylylmethicone.
<6> The content of the component (A) is 7% by mass to 20% by mass.
The content of the component (B) is 0.1% by mass to 0.3% by mass.
When the component (C1) is contained, the content of the component (C1) is 0.8% by mass to 2% by mass.
When the component (C2) is contained, the content of the component (C2) is 0.8% by mass to 2% by mass.
When the component (C3) is contained, the content of the component (C3) is 1% by mass to 3% by mass.
The content of the component (D1) is 1.5% by mass to 3.5% by mass.
The content of the component (D2) is 1.5% by mass to 2.5% by mass.
The antiperspirant composition according to any one of <1> to <5>, wherein the content of the component (E) is 70% by mass to 85% by mass.
<7> The mass ratio (D1 / D2) between the content of the component (D1) and the content of the component (D2) is 0.7 to 2.0. The antiperspirant composition according to any one.
<8> The antiperspirant composition according to any one of <1> to <7>, which is either a roll-on type or a lotion type.

According to the present invention, the above-mentioned problems in the prior art can be solved and the above-mentioned object can be achieved, and after application of the antiperspirant composition, there is no stickiness of the skin, a feeling of tightness of the skin, and no irritation to the skin, and a deodorant effect is obtained. Further, it is possible to provide an antiperspirant composition which is excellent in stability of the preparation and can suppress the white residue of the skin while maintaining the antiperspirant effect.

(Antiperspirant composition)
The antiperspirant composition of the present invention is selected from (A) antiperspirant component, (B) bactericidal component, (C) triglyceride (C1), fatty acid isoamyl (C2), and linear alkyl-modified silicone (C3). At least one of them, (D1) a polyoxyethylene alkyl ether having an average added mole number of 2 or more and 8 or less, and (D2) a polyoxyethylene alkyl ether having an average added mole number of 10 or more and 30 or less of ethylene oxide. In addition, (E) contains water and, if necessary, other components.

<(A) Antiperspirant component>
The antiperspirant component of the component (A) is at least one selected from an aluminum compound, a zirconium compound, and a complex thereof.
The antiperspirant component of the component (A) is contained in order to impart an antiperspirant effect.

Examples of the aluminum compound, the zirconium compound, and a complex thereof include aluminum chloride, aluminum sulfate, aluminum potassium sulfate, aluminum acetate, chlorhydroxyaluminum, allantoinchlorhydroxyaluminum, chlorhydroxyaluminum / propylene glycol complex, and chlorhydroxyaluminum /. Examples include a zirconium / glycine complex. These may be used alone or in combination of two or more.
Among these, chlorhydroxyaluminum, chlorhydroxyaluminum / propylene glycol complex are preferable, and chlorhydroxyaluminum is more preferable, because the antiperspirant effect is more excellent.

The antiperspirant component of the component (A) is not particularly limited, and an appropriately produced one may be used, or a commercially available product may be used. Examples of the commercially available product include chlorhydroxyaluminum (trade name: chlorhydroxyaluminum, manufactured by Taki Chemical Co., Ltd.), chlorhydroxyaluminum-propylene glycol complex (trade name: REHYDROL II, manufactured by Summit Reheis), and potassium aluminum sulfate. (Product name: Karimyoban, manufactured by Taimei Chemicals Co., Ltd.), chlorhydroxyaluminum / zirconium-glycine complex (trade name: Reach AZO-956G, manufactured by Summit Reheis) and the like can be mentioned.

The content of the antiperspirant component of the component (A) is 5% by mass or more with respect to the total amount of the antiperspirant composition from the viewpoint of the antiperspirant effect, the lack of tension of the skin, and the non-stickiness of the skin. 25% by mass is preferable, and 7% by mass to 20% by mass is more preferable. If the content is less than 5% by mass, the antiperspirant effect may be insufficient, and if it exceeds 25% by mass, the skin does not feel taut and the skin is not sticky. Sometimes.

<(B) Bactericidal component>
The bactericidal component of the component (B) is contained in order to impart a deodorizing effect.

Examples of the bactericidal component of the component (B) include cetylpyridinium chloride, benzalkonium chloride, isopropylmethylphenol and the like. These may be used alone or in combination of two or more. Among these, cetylpyridinium chloride and benzalkonium chloride are preferable from the viewpoint of deodorizing effect.
Commercially available products of the bactericidal component of the component (B) include, for example, cetylpyridinium chloride (trade name: cetylpyridinium chloride, manufactured by Wako Pure Chemical Industries, Ltd.), benzalkonium chloride (trade name: Trizon solution, Yamada Pharmaceutical Co., Ltd.). Includes (manufactured by Osaka Kasei Co., Ltd.) and isopropylmethylphenol (trade name: isopropylmethylphenol, manufactured by Osaka Kasei Co., Ltd.).

The content of the component (B) is preferably 0.05% by mass to 0.5% by mass, preferably 0, based on the total amount of the antiperspirant composition from the viewpoint of deodorant effect and no irritation to the skin. .1% by mass to 0.3% by mass is more preferable. If the content is less than 0.05% by mass, the deodorizing effect may be insufficient, and if it exceeds 0.5% by mass, the lack of irritation to the skin may be insufficient.

<(C) At least one selected from triglyceride (C1), fatty acid isoamyl (C2), and linear alkyl-modified silicone (C3)>
At least one selected from the above-mentioned (C) component triglyceride (C1), fatty acid isoamyl (C2), and linear alkyl-modified silicone (C3) is contained to impart no white residue on the skin. To.
As the component (C), it is preferable to use the component (C1) and the component (C2) in combination.

Examples of the triglyceride of the component (C1) include tri (caprylic acid / caprylic acid) glyceryl and caprylic acid triglyceride. These may be used alone or in combination of two or more. Among these, tri (caprylic acid / capric acid) glyceryl is preferable from the viewpoint of no white residue on the skin.

Examples of the fatty acid isoamyl of the component (C2) include isoamyl laurate, isoamyl caprylate, isoamyl caprate, and isoamyl coconut oil fatty acid. These may be used alone or in combination of two or more. Among these, isoamyl laurate, isoamyl caprate, and coconut oil fatty acid isoamyl are preferable, and isoamyl laurate is more preferable, from the viewpoint of no white residue on the skin.

Examples of the linear alkyl-modified silicone of the component (C3) include cetyldimethicone, stearyldimethicone, and caprylylmethicone. These may be used alone or in combination of two or more. Among these, cetyldimethicone is preferable from the viewpoint of no white residue on the skin.

Examples of commercially available products of the component (C1) include tri (caprylic acid / capric acid) glyceryl (trade name: CRODAMOL GTCC, manufactured by Croda Japan Co., Ltd.) and caprylic acid triglyceride (trade name: tricaprylin, Tokyo Chemical Industry Co., Ltd.). (Made by the company) and so on.

Commercially available products of the component (C2) include, for example, isoamyl laurate (trade name: isoamyl laurate, manufactured by Tokyo Kasei Kogyo Co., Ltd.) and isoamyl caprylate (trade name: isoamyl caprylate, manufactured by Tokyo Kasei Kogyo Co., Ltd.). , Isoamyl caprate (trade name: isoamyl caprate, manufactured by Tokyo Kasei Kogyo Co., Ltd.), coconut oil fatty acid isoamyl (trade name: TEGOSOFT AC, manufactured by Evonik Nutrition & Care GmbH) and the like.

Commercially available products of the component (C3) include, for example, cetyldimethicone (trade name: ABIL WAX 9801, manufactured by Evonik Nutrition & Care GmbH), stearyl dimethicone (trade name: ABIL WAX 9800, manufactured by Evonik Nutrition & Care). , Caprilyl methicone (trade name: FZ-3196, manufactured by Toray Dow Corning Co., Ltd.) and the like.

The content of the component (C1) is 0.5% by mass to 3% by mass with respect to the total amount of the antiperspirant composition from the viewpoint of no white residue on the skin, stability of the preparation, and no stickiness on the skin. The mass% is preferable, and 0.8% by mass to 2% by mass is more preferable. If the content is less than 0.5% by mass, the lack of white residue on the skin may be insufficient, and if it exceeds 3% by mass, the stability of the preparation and the non-stickiness of the skin are poor. May be sufficient.

The content of the component (C2) is 0.5% by mass to 3% by mass with respect to the total amount of the antiperspirant composition from the viewpoint of no white residue on the skin, stability of the preparation, and no stickiness on the skin. The mass% is preferable, and 0.8% by mass to 2% by mass is more preferable. If the content is less than 0.5% by mass, the lack of white residue on the skin may be insufficient, and if it exceeds 3% by mass, the stability of the preparation and the non-stickiness of the skin are poor. May be sufficient.

The content of the component (C3) is preferably 0.5% by mass to 5% by mass, based on the total amount of the antiperspirant composition, from the viewpoint of no white residue on the skin and stability of the preparation. More preferably, it is by mass to 3% by mass. If the content is less than 0.5% by mass, the lack of white residue on the skin may be insufficient, and if it exceeds 5% by mass, the stability of the pharmaceutical product may be insufficient.

The mass ratio (C1 / C2) of the content of the component (C1) to the content of the component (C2) is 0.3 to 3 from the viewpoint of the stability of the preparation and the non-stickiness of the skin. 6.6 is preferable, and 0.5 to 2 is more preferable. If the mass ratio is less than 0.3 or more than 3.6, the stability of the pharmaceutical product and the non-stickiness of the skin may be insufficient.

<(D) Polyoxyethylene alkyl ether>
The polyoxyethylene alkyl ether of the component (D) includes a polyoxyethylene alkyl ether having an average number of moles of (D1) ethylene oxide of 2 or more and 8 or less, and a polyoxyethylene alkyl ether having an average number of moles of (D2) ethylene oxide of 10 or more and 30. It contains the following polyoxyethylene alkyl ethers.
The component (D) is contained to improve the stability of the pharmaceutical product.

The average number of moles of the polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added as the component (D1) of 2 or more and 8 or less is preferably 2 or more and less than 5 from the viewpoint of the stability of the pharmaceutical product. If the average number of moles of substance added exceeds 8, the stability of the pharmaceutical product may be insufficient.
There are no commercially available products available for polyoxyethylene alkyl ethers having an average number of moles of ethylene oxide added of less than 2.

The average number of moles of polyoxyethylene alkyl ether with an average number of moles of ethylene oxide added as the component (D2) of 10 or more and 30 or less is 15 or more and 25 from the viewpoint of pharmaceutical stability and non-stickiness of the skin. The following is preferable. If the average number of moles added is less than 10, the stability of the preparation may be insufficient, and if the average number of moles added exceeds 30, the stability of the preparation and the non-stickiness of the skin are insufficient. May become.

The polyoxyethylene alkyl ether having an average addition molar number of ethylene oxide of 2 or more and 8 or less as the component (D1) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, the average addition of ethylene oxide. Examples thereof include polyoxyethylene stearyl ether having 2 or more and 8 or less moles.

The polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added as the component (D2) of 10 or more and 30 or less is not particularly limited and may be appropriately selected depending on the intended purpose. For example, the average addition of ethylene oxide is possible. Examples thereof include polyoxyethylene stearyl ether having 10 or more and 30 or less moles.

Commercially available products of the component (D1) include, for example, Steareth-2 (trade name: EMALEX602) and Steares-3 (trade name: EMALEX602) in which the average number of moles of ethylene oxide added is 2, 3, 5, and 8, respectively. EMALEX603), Steares-5 (trade name: EMALEX605), Steares-8 (trade name: EMALEX608) (all manufactured by Nippon Emulsion Co., Ltd.) and the like.

Commercially available products of the component (D2) include, for example, Steareth-11 (trade name: EMALEX611) and Steareth-15, which have an average number of moles of ethylene oxide added of 11, 15, 16, 20, 25, and 30, respectively. (Product name: EMALEX615), Steares-16 (Product name: EMALEX616), Steares-20 (Product name: EMALEX620), Steares-25 (Product name: EMALEX625), Steares-30 (Product name: EMALEX630) (all) Japan Emulsion Co., Ltd.) and the like.

The content of the component (D1) is preferably 1% by mass to 5% by mass, preferably 1.5% by mass, based on the total amount of the antiperspirant composition from the viewpoint of the stability of the preparation and the non-stickiness of the skin. % To 3.5% by mass is more preferable. If the content is less than 1% by mass, the stability of the pharmaceutical product may be insufficient, and if it exceeds 5% by mass, the non-stickiness of the skin may be insufficient.

The content of the component (D2) is preferably 1% by mass to 3% by mass, preferably 1.5% by mass, based on the total amount of the antiperspirant composition from the viewpoint of the stability of the preparation and the non-stickiness of the skin. % To 2.5% by mass is more preferable. If the content is less than 1% by mass, the stability of the pharmaceutical product may be insufficient, and if it exceeds 3% by mass, the non-stickiness of the skin may be insufficient.

The mass ratio (D1 / D2) of the content of the component (D1) to the content of the component (D2) is preferably 0.4 to 4.0 from the viewpoint of the stability of the pharmaceutical product. 7 to 2.0 is more preferable. If the mass ratio is less than 0.4 or more than 4.0, the stability of the pharmaceutical product may be insufficient.

<(E) Water>
The water of the component (E) is contained to impart stability of the pharmaceutical product.
The water content of the component (E) is 65% by mass to 90% by mass and 70% by mass with respect to the total amount of the antiperspirant composition from the viewpoint of the stability of the preparation and the non-stickiness of the skin. % To 85% by mass is preferable. If the content is less than 65% by mass, the stability of the preparation may be insufficient, and if it exceeds 90% by mass, the non-stickiness of the skin may be insufficient.
Here, the water content of the component (E) is the total content including the water brought in from the components (A) to (D) and other components when they are blended. ..

<Other ingredients>
In addition to the components (A) to (E), the antiperspirant composition of the present invention is usually blended with the antiperspirant composition according to the dosage form as long as the effects of the present invention are not impaired. Other ingredients to be added can be added.
The other components are not particularly limited and may be appropriately selected depending on the intended purpose. For example, other than the oil / fat compound, the wax compound, the silicone compound, the hydrocarbon oil, the higher fatty acid, the higher alcohol, and the component (D). Surfactants, polymers, antioxidants, pigments, emulsion stabilizers, modifiers, preservatives, UV absorbers, chelating agents, moisturizers, thickeners, refreshing agents, anti-inflammatory agents, other than the above-mentioned component (B) Examples include bactericides, amino acids, vitamins, fragrances, and various plant extracts.
The content of the other components is not particularly limited and may be appropriately selected depending on the intended purpose as long as the effects of the present invention are not impaired.

-PH-
The pH of the antiperspirant composition at 25 ° C. is preferably 3 to 4.5 from the viewpoint of antiperspirant effect, no irritation to the skin, and stability of the pharmaceutical product. If the pH is less than 3, the antiperspirant effect and the lack of irritation to the skin may be insufficient, and if it exceeds 4.5, the stability of the pharmaceutical product may be insufficient.

-viscosity-
The viscosity of the antiperspirant composition is not particularly limited and may be appropriately selected depending on the intended purpose. However, from the viewpoint of the stability of the formulation and the non-stickiness of the skin, 1 mPa · s at 25 ° C. It is preferably ~ 3,000 mPa · s, more preferably 5 mPa · s ~ 1,600 mPa · s. If the viscosity is less than 1 mPa · s, the stability of the pharmaceutical product may be insufficient, and if it exceeds 3,000 mPa · s, the non-stickiness of the skin may be insufficient.
The viscosity was measured at 25 ° C. using, for example, a BL type viscometer. It can be measured at 60 rpm for 1 minute using 1 to 4 rotors.

-Production method-
The method for producing the antiperspirant composition of the present invention is not particularly limited, and can be appropriately selected depending on the intended purpose, and can be prepared according to the dosage form. For example, the oil phase containing the component (C) and the component (D) and the aqueous phase containing the component (E) are mixed under temperature conditions equal to or higher than the melting point of the component (D) to form an emulsion. After that, if necessary, the component (A) and the component (B) can be added and mixed with the obtained emulsion.
The device for preparing the antiperspirant composition is not particularly limited and may be appropriately selected depending on the intended purpose. For example, it is provided with a plurality of stirring blades (propeller, turbine, disper, etc.) capable of shearing and total mixing. Examples include a stirring device. The components (A) to (E) and the other components may be used alone in preparing the antiperspirant composition, or a mixture containing two or more kinds of components. It may be used in the state of.

-Dosage form-
The dosage form of the antiperspirant composition is not particularly limited, and examples thereof include a semi-solid type, a gel-like type, and a liquid type. Among these, gel type and liquid type are preferable, and liquid type is preferable because it is effective to apply it to the skin in a state of being dissolved in water, it can be applied with high adhesion, and a high antiperspirant effect can be exhibited. The type is more preferred.
Examples of the semi-solid type include a cream type.
Examples of the gel-like type include a gel type.
Examples of the liquid type include a roll-on type, a lotion type, and a mist type. Among these, the roll-on type and lotion type are preferable from the viewpoint of antiperspirant effect.

When the antiperspirant composition is a roll-on type, the antiperspirant product may be a roll-on container having the antiperspirant composition and a coating ball and filled with the antiperspirant composition. preferable. The roll-on type pharmaceutical product is housed in a known roll-on container, and the antiperspirant composition is attached to the coating ball, which is partially exposed in the roll-on container and is rotatably held by a holder. The coating ball can be adhered to the skin and applied at the time of use.
Further, a gel preparation in which the antiperspirant composition is filled in a bottle container and applied as it is using the container; a gel preparation or a lotion preparation to be applied using a fingertip or a hand can also be preferably used.

-container-
Examples of the container include a roll-on container, a gel bottle container, a lotion bottle container, a mist trigger type spray container, and the like. Among these, a roll-on container is preferable from the viewpoint of antiperspirant effect.
The roll-on container can be suitably used in that the antiperspirant composition can be applied to the skin with high adhesion and an antiperspirant effect can be exhibited. The roll-on container is not particularly limited as long as it can be filled with the antiperspirant composition, and can be appropriately selected depending on the intended purpose. For example, the one described in JP-A-2005-186997. Can be mentioned.

Examples of the roll-on container include a bottle (material: HDPE natural, full filling content: about 56 mL, body diameter: about 33 mm, height: about 87 mm, manufactured by Yoshino Kogyosho Co., Ltd.), a ring (material: LLDPE natural, etc.). Outer diameter: about 26 mm, height: about 18 mm, manufactured by Yoshino Kogyosho Co., Ltd.), balls (material: PP white, diameter: about 20 mm, manufactured by Yoshino Kogyosho Co., Ltd.) and the like can be used.

As the bottle container for lotion, for example, a bottle (trade name: TOMIII-50, material: HDPE natural, full filling content: about 34 mL, body diameter: about 42 mm × 29 mm (oval), height: about 88 mm, Takemoto Container Co., Ltd.), Inner plug (Product name: TO cap nozzle A, Material: PE natural, Outer diameter: Approx. 12 mm, Height: Approx. 13 mm, Takemoto Container Co., Ltd.), Cap (Product name: TOMIII cap, Material: PP white, outer diameter: about 37 mm x 25 mm (oval), height: about 24 mm, manufactured by Takemoto Yohki Co., Ltd.) and the like can be used.

-Use-
The antiperspirant composition of the present invention has no stickiness, skin tension, and irritation to the skin after application of the antiperspirant composition, and is excellent in deodorant effect and stability of the preparation, and also has an antiperspirant effect. Since it can suppress white residue on the skin while maintaining it, it can be applied to, for example, cosmetics, pharmaceuticals, non-pharmaceutical products, etc., and can be used as an antiperspirant, deodorant, antiperspirant deodorant, deodorant. It is suitably available.

Hereinafter, the present invention will be specifically described with reference to examples of the present invention, but the present invention is not limited to these examples. The content of each component described in Examples and Comparative Examples is shown in mass% and is a value converted into pure content.

(Examples 1 to 57 and Comparative Examples 1 to 10)
The antiperspirant compositions of Examples 1 to 57 and Comparative Examples 1 to 10 having the compositions shown in Tables 1 to 10 below were prepared by a conventional method.
40 mL of each obtained antiperspirant composition was filled in a roll-on container having the following specifications to obtain a roll-on type antiperspirant composition.

<Roll-on container>
<< Bottle >>
・ Made by Yoshino Kogyosho Co., Ltd. Material: HDPE Natural, Fully filled content: Approx. 56 mL, Body diameter: Approx. 33 mm, Height: Approx. 87 mm
<< Ring >>
-Made by Yoshino Kogyosho Co., Ltd. Material: LLDPE Natural, Outer diameter: Approx. 26 mm, Height: Approx. 18 mm
<< Ball >>
・ Made by Yoshino Kogyosho Co., Ltd. Material: PP white, diameter: Approximately 20 mm

Next, for each of the obtained roll-on type antiperspirant compositions, the antiperspirant effect, the deodorant effect, the lack of white residue on the skin, the lack of stickiness on the skin, and the lack of tension on the skin are as follows. The non-irritating skin and the stability of the preparation were evaluated. The results are shown in Tables 1 to 10.

<Anti-sweat effect>
For 20 specialized panels, apply 0.5 g of antiperspirant composition to one axilla and exercise with a fitness bike (trade name: FB-300HP, manufactured by Remark) in an environment of 38 ° C and 40% relative humidity. I went for 15 minutes. After that, using a sweat meter (trade name: SKN-2000, manufactured by Nishizawa Electric Meters Manufacturing Co., Ltd.), the amount of sweating in the axilla (sample coating part) to which the sample was applied and the axilla (sample unapplied part) to which the sample was not applied were measured. The measurement was performed, and the antiperspirant rate was calculated from the following formula. The average value of 20 specialized panels was calculated, and the "antiperspirant effect" was evaluated based on the following evaluation criteria.

-Evaluation criteria for antiperspirant effect-
◎ ◎: Mean antiperspirant rate is 56% or more and 100% or less ◎: Mean antiperspirant rate is 46% or more and less than 56% ○: Mean antiperspirant rate is 36% or more and less than 46% △: Antiperspirant Average rate is 26% or more and less than 36% ×: Average antiperspirant rate is 0% or more and less than 26%

<Deodorant effect>
The "deodorant effect" was evaluated based on the following evaluation criteria by the number of people who answered that the deodorant effect was good after applying 0.5 g of each antiperspirant composition to the axilla and drying it to 20 specialized panels. bottom.
-Evaluation criteria for deodorant effect-
◎ ◎: 19 or more and 20 or less of the 20 specialized panels answered that the deodorizing effect was good ◎: 16 or more and 18 or less of the 20 specialized panels answered that the deodorizing effect was good ○: Of the 20 specialized panels 11 or more and 15 or less responded that the deodorizing effect was good △: 6 or more and 10 or less of the 20 specialized panels answered that the deodorizing effect was good ×: 5 or less of the 20 specialized panels had the deodorizing effect Answer good

<No white residue on the skin>
Based on the following evaluation criteria, "skin white" was applied to 20 specialized panels by the number of people who answered that there was no white skin residue after applying 0.5 g of each antiperspirant composition to the axilla and drying it. "There is no rest" was evaluated.
-Evaluation criteria for lack of whiteness on the skin-
◎ ◎: 19 to 20 out of 20 specialized panels answered that there was no white skin residue ◎: 16 to 18 out of 20 specialized panels answered that there was no white skin residue ○: Specialty 11 or more and 15 or less of the 20 panels answered that there was no white skin residue △: 6 or more and 10 or less of the 20 specialized panels answered that there was no white skin residue ×: 20 of the specialized panels 5 or less responded that there was no white residue on the skin

<Non-sticky skin>
Based on the following evaluation criteria, the antiperspirant composition was applied to 20 specialist panels by applying 0.5 g of each antiperspirant composition to the axilla, drying it, and then responding that the skin was not sticky. The "non-stickiness of the skin" after application was evaluated.
-Evaluation criteria for non-greasy skin-
◎ ◎: 19 to 20 out of 20 specialized panels answered that they did not have a sticky skin ◎: 16 to 18 out of 20 specialized panels answered that they did not have a sticky skin ○: Specialty 11 or more and 15 or less of the 20 panel respondents answered that they did not feel sticky on the skin △: 6 or more and 10 or less of the 20 specialized panels answered that they did not feel sticky on the skin ×: Of the 20 specialized panels 5 or less responded that the skin was not sticky

<No feeling of tension on the skin>
Based on the following evaluation criteria, the antiperspirant composition was applied to 20 specialized panels by the number of people who answered that 0.5 g of each antiperspirant composition was applied to the axilla and dried, and then the skin did not feel taut. The "no feeling of tension on the skin" after application was evaluated.
-Evaluation criteria for lack of skin tension-
◎ ◎: 19 to 20 out of 20 specialized panels answered that they did not have a feeling of skin tension ◎: 16 to 18 out of 20 specialized panels answered that they did not have a feeling of skin tension ○: Specialty 11 or more and 15 or less of the 20 panel respondents answered that they did not feel the skin tension △: 6 or more and 10 or less of the 20 specialized panels answered that they did not feel the skin tension ×: Of the 20 specialized panels 5 or less responded that the skin was not taut

<No irritation to the skin>
The antiperspirant composition was based on the following evaluation criteria, depending on the number of people who answered that there was no irritation to the skin after applying 0.5 g of each antiperspirant composition to the axilla and drying it to 20 specialized panels. The "non-irritating skin" after application was evaluated.
-Evaluation criteria for non-irritating skin-
◎ ◎: 19 to 20 out of 20 specialized panels answered that there was no skin irritation ◎: 16 to 18 out of 20 specialized panels answered that there was no skin irritation ○: Specialty 11 or more and 15 or less of the 20 panel respondents answered that they did not irritate the skin △: 6 or more and 10 or less of the 20 specialized panels answered that they did not irritate the skin ×: Of the 20 specialized panels 5 or less responded that there was no irritation to the skin

<Pharmaceutical stability (freeze restoration stability)>
A soft transparent glass bottle (trade name: SV-50A, manufactured by Nichiden Rika Glass Co., Ltd.) with a capacity of 50 g was filled with 40 g of each prepared antiperspirant composition, and stored at -20 ° C for 1 day to be completely frozen. After that, it was left at room temperature for 1 day and naturally thawed. "Pharmaceutical stability" as freeze-restoration stability after repeating this operation 5 times was evaluated based on the following evaluation criteria.
-Evaluation criteria for pharmaceutical stability-
◎ ◎: Water separation and separation are not observed at all ◎: Water separation is observed but separation is not observed ○: Water separation is observed but separation is not observed △: Separation is observed very slightly ×: Separation is observed

(Prescription example 1)
The antiperspirant composition having the composition shown in Table 11 below is prepared by a conventional method, and 40 mL of each obtained antiperspirant composition is filled in a lotion type container having the following specifications, and the roll-on type according to Example 3 is used. The same evaluation as the antiperspirant composition was carried out. The results are also shown in Table 11.

<Lotion: Bottle container>
Filling amount: 40 mL
<< Bottle >>
・ Takemoto Yohki Co., Ltd .: TOMIII-50
Material: HDPE natural, full injection content: approx. 34 mL, body diameter: approx. 42 mm x 29 mm (oval), height: approx. 88 mm
<< Inner plug >>
・ Takemoto Yohki Co., Ltd .: Nozzle A for TO cap
Material: PE natural, outer diameter: about 12 mm, height: about 13 mm
<< Cap >>
-Made by Takemoto Yohki Co., Ltd .: TOMIII Cap Material: PP White, Outer Diameter: Approx. 37 mm x 25 mm (oval), Height: Approx. 24 mm

Details of each component of Examples, Comparative Examples, and Formulation Examples are as shown in Table 12 below.

The antiperspirant composition of the present invention has no stickiness, skin tension, and irritation to the skin after application of the antiperspirant composition, and is excellent in deodorant effect and stability of the preparation, and also has an antiperspirant effect. Since it can suppress white residue on the skin while maintaining it, it can be applied to, for example, cosmetics, pharmaceuticals, non-pharmaceutical products, antiperspirants, deodorants, antiperspirant deodorants, deodorants, etc. It can be suitably used for.

Claims (7)

(A) An aluminum compound, a zirconium compound, and at least one antiperspirant component selected from these complexes, and
(B) Bactericidal component and
(C) Triglyceride (C1) and fatty acid isoamyl (C2 ) ,
(D1) Polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added of 2 or more and 8 or less,
(D2) Polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added of 10 or more and 30 or less,
(E) Contains water and
The mass ratio (C1 / C2) of the content of the component (C1) to the content of the component (C2) is 0.3 or more and 3.6 or less.
An antiperspirant composition having a content of the component (E) of 65% by mass to 90% by mass. The antiperspirant composition according to claim 1, wherein the component (A) is chlorohydroxyaluminum. The antiperspirant composition according to any one of claims 1 to 2, wherein the component (B) is at least one selected from cetylpyridinium chloride, benzalkonium chloride, and isopropylmethylphenol. The component (C1) is at least one selected from tri (caprylic acid / caprylic acid) glyceryl and caprylic acid triglyceride.
The antiperspirant composition according to any one of claims 1 to 3, wherein the component (C2) is at least one selected from isoamyl laurate, isoamyl caprate, and isoamyl coconut oil fatty acid. The content of the component (A) is 7% by mass to 20% by mass.
The content of the component (B) is 0.1% by mass to 0.3% by mass.
The content of the component (C1) is 0.8% by mass to 2% by mass.
The content of the component (C2) is 0.8% by mass to 2% by mass.
The content of the component (D1) is 1.5% by mass to 3.5% by mass.
The content of the component (D2) is 1.5% by mass to 2.5% by mass.
The antiperspirant composition according to any one of claims 1 to 4, wherein the content of the component (E) is 70% by mass to 85% by mass. The system according to any one of claims 1 to 5, wherein the mass ratio (D1 / D2) of the content of the component (D1) to the content of the component (D2) is 0.7 to 2.0. Sweat composition. The antiperspirant composition according to any one of claims 1 to 6, which is either a roll-on type or a lotion type.